Postal ballot also clears remuneration proposal and new ESOP 2026 scheme, strengthening the company’s leadership and talent retention strategy
Former Cipla MD & CEO to lead next phase of growth at science-led CDMO platform; Vivek Sharma transitions to advisory role
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
The change of name has been carried on pursuant to the Scheme of Amalgamation
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
API platform to comprise of RA Chem Pharma, ZCL Chemicals and Avra Laboratories
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
